English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Guidelines recommend treating actinic keratoses ( AK s) as they are recognized as precursors of invasive squamous cell carcinoma.    Objective  The objective of this study was to collect real‐world clinical data on the use of methyl aminolevulinate daylight photodynamic therapy ( MAL DL ‐ PDT ) for the treatment of face and scalp  AK  in Europe.    Methods  A prospective, multicenter, non‐interventional study was conducted in six European countries in patients receiving a single treatment of  MAL DL ‐ PDT  for face and/or scalp  AK . Patient‐reported outcomes were assessed by patient questionnaires at baseline and at 3 months after treatment, efficacy was assessed at 3 months using a 6‐point global improvement scale, and adverse events ( AE ) were recorded at each visit.    Results  Overall, 325 patients were enrolled from 52 investigational centres, 314 of whom attended the 3‐month visit. Most patients had multiple lesions (58.4% had >10 lesions) with lesions mainly located on the scalp (60.0%) and/or forehead (54.2%).  AK s were predominantly grade I (39.4%) or grade  II  (33.2%), and 10.5% of patients had grade  III  lesions. The proportions of patients and physicians that were overall satisfied to very satisfied with the  MAL DL ‐ PDT  treatment were 80.4% and 90.3%, respectively. The vast majority of patients (90.0%) would consider using  MAL DL ‐ PDT  again if needed. Physician‐assessed efficacy at 3 months was at least much improved in 83.5% of patients, with 45.9% of patients requiring no retreatment. Related  AE s were reported in 15% of patients.    Conclusion  Use of  MAL DL ‐ PDT  for multiple face and/or scalp  AK s resulted in high levels of patient and physician satisfaction in clinical practice in Europe, reflecting the good efficacy and high tolerability of this convenient procedure.

journal of the european academy of dermatology and venereology

Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries